Home

Learning from the memory of life

Learning from the memory of life

to develop transformative immune therapeutics

Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune’s pipeline comprises drug candidates for Alzheimer’s disease, amyotrophic lateral sclerosis, fronto-temporal dementia as well as cardiomyopathy and type 2 diabetes.

About Neurimmune

Committed to promote independence in life

Committed to promote independence in life

by pioneering novel treatments

Aducanumab is a human monoclonal antibody against beta amyloid in development for the treatment of Alzheimer’s disease. The U.S. FDA approved aducanumab for the treatment of Alzheimer’s disease.

Aducanumab

Transforming the wisdom of life

Transforming the wisdom of life

into promising drug candidates

Besides aducanumab, Neurimmune’s scientists discovered with the Reverse Translational Medicine technology the anti-SOD1 antibody AP-101 for amyotrophic lateral sclerosis and the anti-ATTR antibody NI006 for ATTR cardiomyopathy. These programs are currently evaluated in clinical trials.

Neurimmune pipeline

Decoding immune memories of life

Decoding immune memories of life

to develop therapeutic antibodies

By using Reverse Translational Medicine™ technology, Neurimmune’s scientists and researchers translate genetic information of lymphocyte transcripts from elderly human donors into therapeutic antibodies. Evolutionarily optimized and wisely elected antibodies with preferred activities combine high affinity with target selectivity, excellent pharmacodynamics and low immunogenicity.

RTM™ Technology Platform

06.03.2024 | Company News

Donald L. Price memorial lecture on cryo-EM structures of disease filaments from human brains to be presented at AD/PD 2024

Read more

31.01.2024 | Press Release

Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer’s disease

Read more

12.10.2023 | Company News

Promising results for NI203, an experimental therapy depleting pathologic IAPP aggregates to protect beta cell health, published in Nature Communications.

Read more

Driven by the passion for life

Driven by the passion for life

to help patients around the world

Roger M Nitsch, MD

CEO

Christoph Hock, MD

CMO

Jan Grimm, PhD

CSO

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue